In the business year of 2018/2019, we spent around EUR 50 million on research and development

Egis launches the first in Russia drug combination treatment for lowering cholesterol levels¹

Hungarian-based Egis Pharmaceuticals PLC launch in Russia the first fixed drug combination of two lipid-lowering agents: rosuvastatin and ezetimibe.

WarningYour browser is out of date. Please, use an updated version! Chrome || Firefox